Yintarui® is the commercial brand name of Linperlisib Tablets, an orally selective PI3Kδ inhibitor developed by YL-Pharma. It blocks the PI3Kδ signaling pathway in B lymphocytes, thereby inhibiting tumor cell proliferation and survival. Main IndicationsTreatment of adult patients with relapsed…
Aiboding® is the Chinese commercial brand name of Cladribine Injection, an antimetabolite purine nucleoside analog developed by Hanhui Pharmaceuticals. It interferes with DNA synthesis and repair, selectively killing rapidly dividing and resting lymphocytes. Main IndicationsTreatment of patients with hairy cell…
Amelie® is the commercial brand name of Almonertinib Mesilate Tablets, an orally active third-generation EGFR tyrosine kinase inhibitor developed by Jiangsu Hansoh Pharmaceutical Group. It selectively inhibits EGFR activating mutations and the T790M resistance mutation to block downstream tumor cell…
Zadaxin® is the commercial brand name of Thymalfasin for Injection, a synthetic thymus-derived immunomodulator developed by SciClone Pharmaceuticals. It regulates T-cell function and enhances the body’s cellular immune response. Main IndicationsAdjuvant treatment of chronic hepatitis B, as well as immunomodulation…
Vfend® is the commercial brand name of Voriconazole Tablets, an orally active triazole antifungal agent developed by Pfizer. It inhibits fungal cytochrome P450-dependent 14α-sterol demethylase to block ergosterol synthesis, exerting broad-spectrum antifungal activity. Main IndicationsTreatment of invasive aspergillosis, serious invasive…
Folotyn® is the commercial brand name of Pralatrexate Injection, an anti-folate anti-metabolite developed by Mundipharma. It inhibits dihydrofolate reductase and other folate-dependent enzymes to block DNA synthesis and induce tumor cell death. Main IndicationsTreatment of relapsed or refractory peripheral T-cell…
Sifrol® is the commercial brand name of Pramipexole Dihydrochloride Sustained-Release Tablets, an orally active non-ergot dopamine agonist developed by Boehringer Ingelheim. It stimulates dopamine receptors to improve motor symptoms and related complications of Parkinson’s disease. Main IndicationsTreatment of idiopathic Parkinson’s…
Cymbalta® is the commercial brand name of Duloxetine Hydrochloride Enteric Capsules, an orally active serotonin-norepinephrine reuptake inhibitor (SNRI) developed by Eli Lilly and Company. It blocks serotonin and norepinephrine reuptake to regulate neurotransmitter levels and improve mood and pain perception.…
Kisunla® is the commercial brand name of Donanemab Injection, a humanized monoclonal antibody developed by Eli Lilly and Company. It targets and clears accumulated amyloid-beta plaques in the brain to slow the progression of Alzheimer’s disease. Main IndicationsTreatment of adult…
Dupixent® is the commercial brand name of Dupilumab Injection, a fully human monoclonal antibody against IL-4Rα developed by Sanofi. It blocks IL-4 and IL-13 signaling to suppress type 2 inflammatory responses. Main IndicationsModerate-to-severe atopic dermatitis, uncontrolled asthma, chronic rhinosinusitis with…